These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10393567)

  • 1. Selection of solid dosage form composition through drug-excipient compatibility testing.
    Serajuddin AT; Thakur AB; Ghoshal RN; Fakes MG; Ranadive SA; Morris KR; Varia SA
    J Pharm Sci; 1999 Jul; 88(7):696-704. PubMed ID: 10393567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D; Müllertz A; Cornett C; Munk T; Sonnergaard J; Rantanen J
    J Pharm Sci; 2014 Mar; 103(3):900-8. PubMed ID: 24436033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of microwave oven heating for prediction of drug-excipient compatibilities and accelerated stability studies.
    Schou-Pedersen AM; Østergaard J; Cornett C; Hansen SH
    Int J Pharm; 2015 May; 485(1-2):97-107. PubMed ID: 25746946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of excipient interactions on solid dosage form stability.
    Narang AS; Desai D; Badawy S
    Pharm Res; 2012 Oct; 29(10):2660-83. PubMed ID: 22707362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and utilization of the drug-excipient chemical compatibility automated system.
    Thomas VH; Naath M
    Int J Pharm; 2008 Jul; 359(1-2):150-7. PubMed ID: 18486368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excipient Stability in Oral Solid Dosage Forms: A Review.
    Darji MA; Lalge RM; Marathe SP; Mulay TD; Fatima T; Alshammari A; Lee HK; Repka MA; Narasimha Murthy S
    AAPS PharmSciTech; 2018 Jan; 19(1):12-26. PubMed ID: 28895106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding drug-excipient compatibility: oxidation of compound A in a solid dosage form.
    Wu Y; Dali M; Gupta A; Raghavan K
    Pharm Dev Technol; 2009; 14(5):556-64. PubMed ID: 19743950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation.
    Airaksinen S; Karjalainen M; Kivikero N; Westermarck S; Shevchenko A; Rantanen J; Yliruusi J
    AAPS PharmSciTech; 2005 Oct; 6(2):E311-22. PubMed ID: 16353990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-excipient compatibility testing using a high-throughput approach and statistical design.
    Wyttenbach N; Birringer C; Alsenz J; Kuentz M
    Pharm Dev Technol; 2005; 10(4):499-505. PubMed ID: 16370179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.
    Stanisz B; Regulska K; Kania J; Garbacki P
    Drug Dev Ind Pharm; 2013 Jan; 39(1):51-61. PubMed ID: 22348774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironmental pH modulation in solid dosage forms.
    Badawy SI; Hussain MA
    J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing.
    Verma RK; Garg S
    J Pharm Biomed Anal; 2005 Jul; 38(4):633-44. PubMed ID: 15967291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ionization states in the microenvironment of solid dosage forms: effect of formulation variables and processing.
    Govindarajan R; Zinchuk A; Hancock B; Shalaev E; Suryanarayanan R
    Pharm Res; 2006 Oct; 23(10):2454-68. PubMed ID: 16933092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Excipient Compatibility Study Through a Novel Vial-in-Vial Experimental Setup: A Benchmark Study.
    Jain S; Shah RP
    AAPS PharmSciTech; 2023 May; 24(5):117. PubMed ID: 37160790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of instrumental evaluation of color for the pre-formulation and formulation of rabeprazole.
    Rhee YS; Park CW; Shin YS; Kam SH; Lee KH; Park ES
    Int J Pharm; 2008 Feb; 350(1-2):122-9. PubMed ID: 17919858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.